Across both dose levels, NYX-2925 was well tolerated in the study, with no concerning safety issues observed. APTX closed Thursday regular trading at $0.60, down $0.09 or 13.03%.

About NYX-2925. NYX-2925 is an investigational, novel oral NMDA receptor positive allosteric modulator (PAM) in Phase 2b clinical development for the treatment of chronic pain.

(RTTNews) - Aptinyx Inc. (APTX) reported results from a phase 2b clinical study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy. NYX-2925 did not achieve ...

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy Results from the Phase 2b study are expected in early to mid 2Q 2022 October 27, 2021 06:47 AM ...